What happened
The FDA Compounding Quality Center of Excellence conducts the Compounding Outsourcing Facilities Annual Study to understand industry perspectives, challenges, and supplier-purchaser dynamics. Each study combines a survey, stakeholder discussions, and analysis of existing data; a research partner works under FDA direction, and survey and discussion data are anonymous to FDA. Published summaries describe a relatively stable but evolving sector, continued customer demand, and wide variation in CGMP expertise, resources, and growth capacity. Studies also found differing familiarity with FDA quality expectations and demand for more two-way communication. FDA responded with expanded CGMP training, conference sessions on inspections, analytical testing, SOPs, and stability BUDs, plus stakeholder and listening forums.
Why it matters
For pharmaceutical manufacturers and outsourcing facilities, the findings may matter because uneven CGMP knowledge and resources can affect how consistently firms understand and implement quality practices. FDA’s training and communication activities identify practical areas of attention, including inspection readiness, analytical testing, SOPs, and stability BUDs. The study also provides anonymous industry feedback that may inform FDA’s future policy and programmatic work, although the page does not establish new requirements.
Key topics: Compounding Outsourcing Facilities Annual Study, Outsourcing facility CGMP knowledge and challenges, FDA training and stakeholder communication